Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: vogel w. Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. doi: 10.1053/j.gastro.2009.10.058. Epub 2009 Nov 10. Gastroenterology. 2010. PMID: 19909752 Clinical Trial.
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Steindl-Munda P, Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Gangl A, Vogel W; Austrian Hepatitis Study Group. Steindl-Munda P, et al. Among authors: vogel w. Liver Int. 2003 Aug;23(4):269-75. doi: 10.1034/j.1600-0676.2003.00838.x. Liver Int. 2003. PMID: 12895267 Clinical Trial.
Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.
Gschwantler M, Laferl H, Vogel W, Korak W, Moser S, Hofer H, Bauer B, Schleicher M, Bognar B, Bischof M, Stauber R, Maieron A, Ferenci P; Austrian Hepatitis Study Group. Gschwantler M, et al. Among authors: vogel w. Wien Klin Wochenschr. 2018 Jan;130(1-2):54-61. doi: 10.1007/s00508-017-1263-2. Epub 2017 Sep 12. Wien Klin Wochenschr. 2018. PMID: 28900714
Combination of interferon induction therapy and ribavirin in chronic hepatitis C.
Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Munda-Steindl P, Hegenbarth K, Gangl A, Vogel W; Australian Hepatitis Study Group. Ferenci P, et al. Among authors: vogel w. Hepatology. 2001 Nov;34(5):1006-11. doi: 10.1053/jhep.2001.28706. Hepatology. 2001. PMID: 11679972 Clinical Trial.
Long-term outcomes of patients with Wilson disease in a large Austrian cohort.
Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R, Maieron A, Datz C, Steindl-Munda P, Hofer H, Vogel W, Trauner M, Ferenci P. Beinhardt S, et al. Among authors: vogel w. Clin Gastroenterol Hepatol. 2014 Apr;12(4):683-9. doi: 10.1016/j.cgh.2013.09.025. Epub 2013 Sep 25. Clin Gastroenterol Hepatol. 2014. PMID: 24076416
Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
Stern R, Hametner S, Ramona AZ, Moser S, Karpi A, Laferl H, Stauber RE, Zoller HM, Maieron A, Vogel W, Graziadei I, Gschwantler M, Kozbial K, Freissmuth C, Hofer H, Ferenci P. Stern R, et al. Among authors: vogel w. Am J Gastroenterol. 2016 May;111(5):744-5. doi: 10.1038/ajg.2016.39. Am J Gastroenterol. 2016. PMID: 27151123 No abstract available.
Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P, Stauber R, Propst A, Fiedler R, Müller C, Gschwantler M, Schütze K, Datz C, Judmaier G, Vogel W, Krejs GJ, Gangl A. Ferenci P, et al. Among authors: vogel w. Dig Dis Sci. 1996 Dec;41(12 Suppl):103S-108S. doi: 10.1007/BF02087884. Dig Dis Sci. 1996. PMID: 9011466 Clinical Trial.
1,594 results